This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Webinars

Explore our recorded webinars' library to listen to UK and international experts present their clinical experience on management of critically ill patients with MDR Gram-negative infections.

Professor Matteo Bassetti and  Philippe Montravers

Matteo Bassetti, Professor of Infectious Diseases, University of Genoa and Philippe Montravers, Head of the Department of Anaesthesia and Critical Care Medicine Unit, at Assistance Publique Hospitaux Paris, present risk stratification in infectious diseases and its role in achieving a truly patient-centric approach.

Card CTA

** This is an optional area where footnotes can live.

David Jenkins and Maha Albur

David Jenkins, Consultant Medical Microbiologist, University Hospital of Leicester and Dr Maha Albur, Consultant Physician Infectious Disease and Microbiology North Bristol NHS Trust present the evolving Gram-negative resistance landscape in the UK, and share their experience on managing an OXA-48 outbreak.

Card CTA

** This is an optional area where footnotes can live.

Antoni Torres

Professor Antoni Torres, Department of Pulmonology and Respiratory Allergy, Clinic of Barcelona, Spain, shares his experience in treating HAP/VAP in critically ill patients, discusses the importance of identifying risk factors and using local epidemiology patterns to enable early adequate therapy.

Card CTA

** This is an optional area where footnotes can live.

Luke Moore

Dr Luke Moore, Infectious Diseases Consultant at Chelsea and Westminster, presents the importance of risk stratification and screening for resistant Gram-negative infections.

Card CTA

** This is an optional area where footnotes can live.

Louise Sweeney

Dr Louise Sweeney, Consultant Clinical Microbiologist, presents the management of difficult-to-treat bacterial infections, resistance patterns including her experience on managing resistance in Manchester.

Card CTA

** This is an optional area where footnotes can live.

David Jenkins

David Jenkins, Consultant Medical Microbiologist, University Hospital of Leicester discusses resistance mechanisms and outbreaks in the UK. He explores the evolving Gram-negative resistance landscape in the UK, shares his experience of an OXA-48 outbreak and the importance of avoiding outbreaks through effective antimicrobial stewardship.

Card CTA

** This is an optional area where footnotes can live.

Andy Dodgson

Dr Andrew Dodgson, Consultant Microbiologist at Manchester, presents his perspective on early effective intervention in critically ill patients with MDR Gram-negative infections.

Card CTA

** This is an optional area where footnotes can live.

Luke Moore and Miguel Sanchez Garcia

Dr Luke Moore and Miguel Sanchez Garcia discuss clinical effectiveness of ZAVICEFTA in treating severe Gram-negative infections.

Card CTA

** This is an optional area where footnotes can live.

Explore more

Access other case studies & videos

  • KOL Videos - Zavicefta
  • KOL Videos - Gram-negative
  • KOL Videos - Clinical experience
View Support & Services

Abbreviations:

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; AMR, Antimicrobial Resistance; AMS, Antimicrobial Stewardship

Prescribing information

Zavicefta® (ceftazidime and avibactam) 2g/0.5 g Powder for Concentrate for Solution for Infusion

Cresemba (isavuconazole)
Great Britain
Cresemba (isavuconazole) 100mg hard capsules
Cresemba (isavuconazole) 200mg powder for concentrate for solution for infusion
Northern Ireland
Cresemba (Isavuconazole) 100mg hard capsules and Cresemba (Isavuconazole) 200mg powder for concentrate for solution for infusion

Zinforo® (ceftaroline fosamil)
Great Britain
Zinforo 600 mg powder for concentrate for solution for infusion
Northern Ireland
Zinforo 600 mg powder for concentrate for solution for infusion ​​​​​​​

Meronem® (meropenem triydrate) IV 1g
Meronem® (meropenem triydrate) IV 500mg

Tazocin® (piperacillin sodium, tazobactam sodium) 2g/0.25g Powder for Solution for Infusion
Tazocin® (piperacillin sodium, tazobactam sodium) 4g/0.5g Powder for Solution for Infusion

Tygacil (tigecycline) 50mg powder for solution for infusion

Amikacin (amikacin sulfate) 500mg/2ml solution for injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial pack £60.00
Click here for the Summary of Product Characteristics 

Gentamicin (gentamicin sulfate) 40 mg/ml Injection
Legal Category: Prescription Only Medicine (POM)
NHS Price: 5 vial £20.00 
Click here for the Summary of Product Characteristics

Ciprofloxacin (ciprofloxacin lactate) 2 mg/ml Solution for Infusion
Legal Category: Prescription Only Medicine (POM)
NHS Price: 10 bag £200.00 
Click here for the Summary of Product Characteristics

Zyvox (linezolid) 2mg/ml Solution for Infusion    
Zyvox (linezolid)  600mg Film-Coated Tablets
Zyvox (linezolid) 100mg/5ml Granules for Oral Suspension

Dalacin C (clindamycin hydrochloride) 150mg capsules
Dalacin C (clindamycin hydrochloride) 75mg capsules
Dalacin C (clindamycin phosphate)  sterile solution for injection
Dalacin T (clindamycin phosphate) 1% topical lotion
Dalacin (clindamycin phosphate) 2% cream

Zithromax (azithromycin dihydrate) 250 mg capsules
Zithromax (azithromycin dihydrate) 200mg/5ml oral suspension

Tobramycin (tobramycin)
Tobramycin 240mg/6ml solution for injection
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 1 vial £19.20
Click here for the Summary of Product Characteristics

Tobramycin 80mg/2ml solution for injection
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 5 vial £20.80
Click here for the Summary of Product Characteristics

Aciclovir (aciclovir sodium)
Aciclovir 25 mg/ml Concentrate for Solution for Infusion vials
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 5 vials £50.00
Click here for the Summary of Product Characteristics

Aciclovir 1 g/40 ml solution for infusion vials 
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 1 vial £40.00
Click here for the Summary of Product Characteristics

Aciclovir 250 mg/ 10 ml Concentrate for Solution for Infusion vials
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 5 vials  £50.0
Click here for the Summary of Product Characteristics

Aciclovir 500 mg/20 ml Solution for Infusion vials
Legal Category: Prescription Only Medicine (POM) 
Basic NHS Cost: 5 vials £100.00
Click here for the Summary of Product Characteristics

Ecalta® (anidulafungin) 100 mg Powder for Concentrate for Solution for Infusion

Diflucan® (fluconazole) 10 mg/ml powder for oral suspension
Diflucan® (fluconazole) 150 mg capsules
Diflucan® (fluconazole) 200 mg hard capsules
Diflucan® (fluconazole) 50 mg hard capsules
Diflucan® (fluconazole)  40 mg/ml powder for oral suspension

Vfend (voriconazole) 50mg film coated tablets
Vfend (voriconazole) 200mg film coated tablets
Vfend (voriconazole) 200mg powder for solution for infusion
Vfend (voriconazole) 40mg/ml powder for oral suspension

PP-ZVA-GBR-1283. September 2021

Join us!

Follow the link to learn about out upcoming meetings and online webinars event - dates, location and agendas.

Register here

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

  • REPROVE Phase III trial (HAP/VAP)

  • RECLAIM Phase III trial (cIAI)

  • RECAPTURE Phase III trial (cUTI)​​​​​​​

  • REPRISE Phase III trial (cIAI and cUTI)

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View safety profile

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No